Abiopharma

🔍 Kaye Edward M. MD (Executive)

Company: Stoke Therapeutics, Inc. (STOK)

Report Date: 2025-08-29

Detailed Transactions and Holdings:

• Sold 1,029 shares of Common Stock at $20.0 per share (Direct)
  Date: 2025-08-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 152,441.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 14,860 shares of Common Stock at $20.1386 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 137,581.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 45,996 shares of Common Stock at $20.1291 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 91,585.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive.